OR WAIT null SECS
December 01, 2006
The refusal to sell was motivated by a desire to maximize GSK's profits, and GSK had not shown that not having these profits would prejudice consumers by restricting GSK's R&D.
November 02, 2006
Yet again, FDA's ability to regulate drugs is under fire. At the core of this latest round of scrutiny is whether the agency has the resources to properly control the safety of new nanotech-based drug products.
Here's to all the difficult, out-of-touch, and irresponsible coworkers that make our workplace interesting.
The reason for reading the report is to inoculate ourselves against error.
Branded pharmaceutical companies have long been immune to the cost pressures faced in other industries. With robust research and development pipelines, long periods of patent protection to ensure continued high margins, and a regulatory environment that has virtually eliminated the threat of overseas competition, pharmaceutical companies have traditionally considered spend management an afterthought. Recent changes in the pharmaceutical industry, however, have begun to erode Big Pharma's once-imperious position.
October 02, 2006
Whether you advance your technology from concept to commercialization or use a third party for parts or all of this work, the ability to do technology transfer flawlessly is essential to successful, efficient pharmaceutical production.
Much is riding on the market success or failure of Pfizer's Exubera inhalable insulin.
Getting "swamped at work" takes on an entirely new meaning for these GMP Agents.
Teamwork, communication, and trust are as important as the technology.
September 02, 2006
I recently embarked on a quest: to investigate industry's use of the words, "generic" and "biosimilar" when describing a biologic molecule. An English major at heart, I was wrapped up in a news story that was partly about science, partly about words.